Episode
Deep Dive: What FDA’s QMSR Warning Letters Are Revealing
- Podcast
- Let's Talk Risk! Podcast
- Published
- Sep 11, 2026
- Duration seconds
- 1273
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-what-fda-s-qmsr-warning-letters-are-revealing.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
If you’re trying to manage risk in isolated silos, your quality management system is already obsolete. What happens when a supplier changes a device label without triggering design controls? When operators quietly rework nonconforming product? Or when serious post-market signals never make it back into the risk file? This Deep Dive examines recent FDA inspection and warning-letter examples through one common lens: the integration of risk management across the quality system. The cases illustrate how seemingly separate failures in supplier controls, manufacturing, complaints, nonconforming product, CAPA, and infrastructure can become connected risk-management failures under QMSR. Key highlights covered in the audio: * Why ISO 13485 Clause 7.1 is becoming so important — and how risk management increasingly connects multiple parts of the QMS. * Supplier changes can become risk-management events when labeling, intended use, or other product assumptions change without adequate escalation. * Undocumented shop-floor rework can hide risk signals , leaving management metrics looking healthy while process problems accumulate. * CAPA cannot work in isolation when environmental controls, process data, nonconformances, and risk analyses are disconnected. * A static risk file is no longer enough. Post-market experience, manufacturing changes, supplier issues, and emerging hazards must continually inform lifecycle risk management. The broader lesson is straightforward: QMSR is pushing companies away from managing compliance clause by clause and toward managing risk as an interconnected system. And that raises an important question for medical device organizations: When a new signal appears anywhere in your quality system, can it actually find its way back to the assumptions in your r…